Litcius/Paper detail

Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)

Jiao Deng, Wei Jiang, Liang Liu, Wenli Zhan, Yudi Wu, Xiang Xu

2022Oncology Letters14 citationsDOIOpen Access PDF

Abstract

Programmed death ligand 1 (PD-L1) is widely expressed in human tumors. It is widely known for its immunosuppressive function as it can help tumor cells evade T cell immune killing through the PD-1/PD-L1 signal. A number of clinical trials have proved that the destruction of the combination of PD-1 and PD-L1 by antibodies could significantly affect patients with advanced cancer. However, a number of patients with cancer still cannot benefit from PD-1/PD-L1 blocking therapy. The main reason is that PD-L1 also has some intrinsic regulatory functions to promote the progression of tumors. PD-L1 Protein contains an intrinsic domain that could link to other signal pathways, but the mechanism has not yet been fully revealed. The present review mainly discussed the non-immune checkpoint functions of PD-L1, such as its role in regulating cell proliferation, cell metabolism, drug resistance and maintaining epithelial-mesenchymal transition and stemness.

Topics & Concepts

Molecular medicineOncogeneImmune systemCell cycleFunction (biology)CancerBiologyCancer researchComputational biologyImmunologyCell biologyGeneticsCancer Immunotherapy and BiomarkersImmune Cell Function and InteractionImmune cells in cancer